FDA clears Abbott CardioMEMS app features for heart failure patients
Tweet Send to a Friend
Abbott (NYSE: ABT) received U.S. Food and Drug Administration approval for updates to its CardioMEMS HF System that allow heart ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




